Table 2. Methylation status of VDAC2 in human sperm in NZ and IAS group.
| Groups | Status of methylation | CpG1 a%(n/N) | CpG2a%(n/N) | CpG3a%(n/N) | CpG4a%(n/N) | CpG5a%(n/N) | CpG6a%(n/N) | CpG7a%(n/N) |
|---|---|---|---|---|---|---|---|---|
| NZ | Complete unmethylation (0%)** | 74.07%(200/270) | 76.67%(207/270) | 75.19%(203/270) | 86.30%(233/270) | 86.67%(234/270) | 84.81%(229/270) | 90.37%(244/270) |
| Mild methylation (0–20%)* | 7.41%(20/270) | 8.15%(22/270) | 9.26%(25/270) | 6.67%(18/270) | 11.85%(32/270) | 10.74%(29/270) | 7.04%(19/270) | |
| Moderate methylation (20–80%)** | 18.52%(50/270) | 15.19%(41/270) | 15.56%(42/270) | 7.04%(19/270) | 1.48%(4/270) | 4.44%(12/270) | 2.59%(7/270) | |
| Severe methylation (80–100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total (N) | 270 | 270 | 270 | 270 | 270 | 270 | 270 | |
| Groups | Status of methylation | CpG1a%(n/N) | CpG2a%(n/N) | CpG3a%(n/N) | CpG4a%(n/N) | CpG5a%(n/N) | CpG6a%(n/N) | CpG7a%(n/N) |
| IAS | Complete unmethylation (0%) | 64.00%(160/250) | 69.20%%(173/250) | 63.60%(159/250) | 80.80%(202/250) | 75.60%(189/250) | 72.80%(182/250) | 80.80%(202/250) |
| Mild methylation (0–20%) | 3.60%(9/250) | 6.40%(16/250) | 4.00%(10/250) | 6.40%(16/250) | 6.00%(15/250) | 4.40%(11/250) | 8.80%(22/250) | |
| Moderate methylation (20–80%) | 32.40%(81/250) | 24.40%(61/250) | 29.20%(73/250) | 12.80%(32/250) | 18.40%(46/250) | 22.80%(57/250) | 10.40%(26/250) | |
| Severe methylation (80–100%) | 0 | 0 | 3.20% (8/250) | 0 | 0 | 0 | 0 | |
| Total (N) | 250 | 250 | 250 | 250 | 250 | 250 | 250 | |
| Groups | Status of methylation | CpG8a%(n/N) | CpG9a%(n/N) | CpG10a%(n/N) | CpG11a%(n/N) | CpG12a%(n/N) | CpG13a%(n/N) | CpG14a%(n/N) |
| NZ | Complete unmethylation (0%)** | 88.15%(238/270) | 80.74%(218/270) | 89.26%(241/270) | 77.78%(210/270) | 88.15%(238/270) | 83.33 (225/270) | 89.63%(242/270) |
| Mild methylation (0–20%)* | 8.15%(22/270) | 8.15%(22/270) | 8.15%(22/270) | 9.26%(25/270) | 8.15%(22/270) | 10.00%(27/270) | 9.26%(25/270) | |
| Moderate methylation (20–80%)** | 3.70%(10/270) | 11.11%(30/270) | 2.59%(7/270) | 12.96%(35/270) | 3.70%(10/270) | 6.67%(18/270) | 1.11%(3/270) | |
| Severe methylation (80–100%) | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total (N) | 270 | 270 | 270 | 270 | 270 | 270 | 270 | |
| Groups | Status of methylation | CpG1a%(n/N) | CpG2a%(n/N) | CpG3a%(n/N) | CpG4a%(n/N) | CpG5a%(n/N) | CpG6a%(n/N) | CpG7a%(n/N) |
| IAS | Complete unmethylation (0%) | 81.60%(204/250) | 76.40%(191/250) | 85.20%(213/250) | 69.60%(174/250) | 80.80%(202/250) | 72.80%(182/250) | 86.40%(216/250) |
| Mild methylation (0–20%) | 8.00%(20/250) | 8.80%(22/250) | 10.40%(26/250) | 5.60%(14/250) | 8.00%(20/250) | 6.40%(16/250) | 9.60%(24/250) | |
| Moderate methylation (20–80%) | 10.40%(26/250) | 14.80%(37/250) | 4.40%(11/250) | 24.80%(62/250) | 11.20%(28/250) | 20.80%(52/250) | 4.00%(10/250) | |
| Severe methylation (80–100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total (N) | 250 | 250 | 250 | 250 | 250 | 250 | 250 |
CpG:—C—phosphate—G—; NZ: normozoospermia; IAS: idiopathic asthenospermia; Statistically significant differences from the control group (NZ) were represented with asterisks: *P < 0.05, **P < 0.01.